GSTP1 and female reproductive organ cancer: Perhaps worth to mention is a comprehensive pharmacogenomic analysis in 320 gynecological cancers patients, of which GSTP1 rs1695 showed the lowest p-value against severe hematological toxicity (p = 0.00034) (Yoshihama et al., 2018).